SLC5A2 and diabetic ketoacidosis: Future studies should specifically examine changes in sodium levels following SGLT-2 inhibitor initiation, as well as the incidence of recurrent urinary tract infections and euglycemic diabetic ketoacidosis, given that these are known adverse effects of this drug class.